Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15086540 | 1.00 | PNMT (0.53) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| SCHEMBL29495985 | 1.00 | PNMT (0.53) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| SCHEMBL24452647 | 1.00 | PNMT (0.53) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| Hydrochloric Acid SCHEMBL3588397 | 0.98 | PNMT (0.51) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| Hydrochloric Acid SCHEMBL16536351 | 0.98 | PNMT (0.51) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| SCHEMBL31137516 | 0.90 | CYP11B1 (0.51) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| SCHEMBL15335678 | 0.90 | CYP11B1 (0.51) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| SCHEMBL15335680 | 0.90 | CYP11B1 (0.51) | PNMTSRD5A1CYP11B1CYP11B2AADAT | |
| SCHEMBL11522388 | 0.86 | PNMT (0.53) | PNMTCYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL15335796 | 0.86 | PNMT (0.53) | PNMTCYP11B1CYP11B2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105175271-A | Method for preparing S-5-trifluoromethyl-1-aminoindane | WU LING | 2015-12-23 | — | — | CN | claimed |
| CN-105175270-A | Method for preparing R-5-trifluoromethyl-1-aminoindane | WU LING | 2015-12-23 | — | — | CN | claimed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| CN-114206335-B | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240245691-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SITRYX THERAPEUTICS LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4330231-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION | Sitryx Therapeutics Limited (GB) | 2024-03-06 | — | — | EP | disclosed |
| EP-4272836-A2 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022229617-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION | SITRYX THERAPEUTICS LIMITED (GB) | 2022-11-03 | — | — | WO | disclosed |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| EP-1658269-B1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-7015233-B2 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060035934-A1 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040254188-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-12-16 | — | — | US | disclosed |
| US-4132737-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | PNMT 815/4885SRD5A1 1055/4885CYP11B1 1569/4885 |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | PNMT 250/4885SRD5A1 3372/4885CYP11B1 2958/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | PNMT 217/4885SRD5A1 1299/4885CYP11B1 1825/4885 |
| US-20240245691-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | HCAR2, NFKBIA, TNF | PNMT 3984/4885SRD5A1 50/4885CYP11B1 191/4885 |
| US-20060035934-A1 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | TRPV1, TRPV2, OPRL1 | PNMT 1471/4885SRD5A1 1122/4885CYP11B1 1887/4885 |
| US-20040254188-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, TRPV2 | PNMT 2009/4885SRD5A1 960/4885CYP11B1 1676/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | PNMT 4243/4885SRD5A1 475/4885CYP11B1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.